David Gewirtz

Dr. David Gewirtz

Department of Pharmacology and Toxicology and Medicine, Virginia Commonwealth University, Richmond, VA 23284, USA
orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2021 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
DKDaniel J. Klionsky
Daniel J. Klionsky
GPGiulia Petroni
Giulia Petroni
RARavi K Amaravadi
Ravi K Amaravadi
EBEric H Baehrecke
Eric H Baehrecke
ABAndrea Ballabio
Andrea Ballabio
FPFederico Pietrocola
Federico Pietrocola
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

1 April 2021 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
PPPataje G Prasanna
Pataje G Prasanna
DCDeborah E Citrin
Deborah E Citrin
JHJeffrey Hildesheim
Jeffrey Hildesheim
MAMansoor M Ahmed
Mansoor M Ahmed
SVSundar Venkatachalam
Sundar Venkatachalam
CCC Norman Coleman
C Norman Coleman
Cellular senescence is an essential tumor suppressive mechanism that prevents the propagation of oncogenically activated, genetically unstable, and/or damaged cells. Induction of tumor cell senescence is also one of the underlying mechanisms by which cancer therapies exert antitumor activity. However, an increasing body of evidence from preclinical studies demonstrates that radiation and chemotherapy cause accumulation of senescent cells (SnCs) both in tumor and normal tissue. SnCs in tumors can, paradoxically, promote tumor relapse, metastasis, and resistance to therapy, in part, through expression of the senescence-associated secretory phenotype. In addition, SnCs in normal tissue can contribute to certain radiation- and chemotherapy-induced side effects. Because of its multiple roles, cellular senescence could serve as an important target in the fight against cancer. This commentary provides a summary of the discussion at the National Cancer Institute Workshop on Radiation, Senescence, and Cancer (August 10-11, 2020, National Cancer Institute, Bethesda, MD) regarding the current status of senescence research, heterogeneity of therapy-induced senescence, current status of senotherapeutics and molecular biomarkers, a concept of “one-two punch” cancer therapy (consisting of therapeutics to induce tumor cell senescence followed by selective clearance of SnCs), and its integration with personalized adaptive tumor therapy. It also identifies key knowledge gaps and outlines future directions in this emerging field to improve treatment outcomes for cancer patients.

29 March 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Tareq SalehTareq Saleh
Tareq Saleh
SBSarah Bloukh
Sarah Bloukh
VCValerie Carpenter
Valerie Carpenter
EREnas Refat
Enas Refat
JBJomana Bakeer
Jomana Bakeer
David GewirtzDavid Gewirtz
David Gewirtz
For the past two decades, cellular senescence has been recognized as a central component of the tumor cell response to chemotherapy and radiation. Traditionally, this form of senescence, termed Therapy-Induced Senescence (TIS), was linked to extensive nuclear damage precipitated by classical genotoxic chemotherapy. However, a number of other forms of therapy have also been shown to induce senescence in tumor cells independently of direct genomic damage. This review attempts to provide a comprehensive summary of both conventional and targeted anticancer therapeutics that have been shown to induce senescence in vitro and in vivo. Still, the utility of promoting senescence as a therapeutic endpoint remains under debate. Since senescence represents a durable form of growth arrest, it might be argued that senescence is a desirable outcome of cancer therapy. However, accumulating evidence suggesting that cells have the capacity to escape from TIS would support an alternative conclusion, that senescence provides an avenue whereby tumor cells can evade the potentially lethal action of anticancer drugs, allowing the cells to enter a temporary state of dormancy that eventually facilitates disease recurrence, often in a more aggressive state. Furthermore, TIS is now strongly connected to tumor cell remodeling, potentially to tumor dormancy, acquiring more ominous malignant phenotypes and accounts for several untoward adverse effects of cancer therapy. Here, we argue that senescence represents a barrier to effective anticancer treatment, and discuss the emerging efforts to identify and exploit agents with senolytic properties as a strategy for elimination of the persistent residual surviving tumor cell population, with the goal of mitigating the tumor-promoting influence of the senescent cells and to thereby reduce the likelihood of cancer relapse.

1 October 2008 in Biochemical Pharmacology
Verified
Journal Article
Closed access
David GewirtzDavid Gewirtz
David Gewirtz
SHShawn E. Holt
Shawn E. Holt
LELynne W. Elmore
Lynne W. Elmore

15 March 2019 in Cancer Research
Verified
Journal Article
Open access
PDF file
Tareq SalehTareq Saleh
Tareq Saleh
LTLiliya Tyutyunyk-Massey
Liliya Tyutyunyk-Massey
David GewirtzDavid Gewirtz
David Gewirtz
Senescence, a durable form of growth arrest, represents a primary response to numerous anticancer therapies. Although the paradigm that senescence is “irreversible” has largely withstood the findings of tumor cell recovery from what has been termed “pseudo-senescence” or “senescence-like arrest,” a review of the literature suggests that therapy-induced senescence in tumor cells is not obligatorily a permanent cell fate. Consequently, we propose that senescence represents one avenue whereby tumor cells evade the direct cytotoxic impact of therapy, thereby allowing for prolonged survival in a dormant state, with the potential to recover self-renewal capacity and contribute to disease recurrence.

24 March 2024 in Autophagy
Verified
Journal Article
Open access
XCXin Chen
Xin Chen
ATAndrey S. Tsvetkov
Andrey S. Tsvetkov
HSHan-Ming Shen
Han-Ming Shen
CICiro Isidoro
Ciro Isidoro
NKNicholas T. Ktistakis
Nicholas T. Ktistakis
DTDaolin Tang
Daolin Tang
Maintaining a delicate balance between cell survival and cell death is essential for the normal biological functions of living organisms. The disruption in this equilibrium can be pathogenic. For e...